Wealth Alliance Sells 1,786 Shares of Kenvue Inc. (NYSE:KVUE)

Wealth Alliance lowered its stake in Kenvue Inc. (NYSE:KVUE) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,292 shares of the company’s stock after selling 1,786 shares during the quarter. Wealth Alliance’s holdings in Kenvue were worth $668,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in KVUE. State Street Corp raised its stake in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after buying an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Holocene Advisors LP grew its holdings in Kenvue by 75.5% during the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares in the last quarter. M&G PLC boosted its holdings in shares of Kenvue by 538.0% in the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after purchasing an additional 3,660,730 shares during the period. Finally, FMR LLC lifted its stake in shares of Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.5 %

Shares of KVUE stock opened at $22.38 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The stock’s fifty day moving average price is $21.29 and its 200 day moving average price is $22.14. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $42.90 billion, a price-to-earnings ratio of 42.22, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.66%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KVUE. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group decreased their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.